{"filing":{"accession_number":"0001193125-26-331556","cik":"0001583648","ticker":"PVLA","company_name":"PALVELLA THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"pvla-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1583648/000119312526331556/pvla-20260804.htm"},"events":[{"id":23866,"run_id":21587,"accession_number":"0001193125-26-331556","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Palvella Therapeutics reported second quarter 2026 financial results, including R\u0026D expenses of $12.5M, G\u0026A expenses of $8.9M, a net loss of $21.9M ($1.52 per share), and a cash position of $250.6M as of June 30, 2026, along with operational and clinical development updates.","company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24216,"accession_number":"0001193125-26-331556","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 ending June 30, 2026, disclosed via Item 2.02 and furnished as a press release exhibit (EX-99.1). The filing reports financial results including R\u0026D expenses ($12.5M), G\u0026A expenses ($8.9M), net loss ($21.9M), and cash position ($250.6M), along with operational and clinical development updates. This is a standard earnings disclosure material to investors assessing the company's financial condition and progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:23:37.480224+00:00","company_name":"","ticker":null,"filing_date":""},{"id":24217,"accession_number":"0001193125-26-331556","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Palvella Therapeutics' second quarter 2026 financial results, including Q2 2026 R\u0026D expenses ($12.5M), G\u0026A expenses ($8.9M), net loss ($21.9M or $1.52 per share), and cash position ($250.6M as of June 30, 2026). The press release (EX-99.1) explicitly states \"Palvella Therapeutics Reports Second Quarter 2026 Financial Results\" and provides detailed financial metrics alongside a corporate update. This is a standard earnings release disclosure material to investors assessing the company's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:23:37.480224+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24216,"accession_number":"0001193125-26-331556","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 ending June 30, 2026, disclosed via Item 2.02 and furnished as a press release exhibit (EX-99.1). The filing reports financial results including R\u0026D expenses ($12.5M), G\u0026A expenses ($8.9M), net loss ($21.9M), and cash position ($250.6M), along with operational and clinical development updates. This is a standard earnings disclosure material to investors assessing the company's financial condition and progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:23:37.480224+00:00","company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","filing_date":"2026-08-04"},{"id":24217,"accession_number":"0001193125-26-331556","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Palvella Therapeutics' second quarter 2026 financial results, including Q2 2026 R\u0026D expenses ($12.5M), G\u0026A expenses ($8.9M), net loss ($21.9M or $1.52 per share), and cash position ($250.6M as of June 30, 2026). The press release (EX-99.1) explicitly states \"Palvella Therapeutics Reports Second Quarter 2026 Financial Results\" and provides detailed financial metrics alongside a corporate update. This is a standard earnings release disclosure material to investors assessing the company's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:23:37.480224+00:00","company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","filing_date":"2026-08-04"}]}